Proton pump inhibitors for acid suppression in the intensive care unit: Formulary considerations

American Journal of Health-System Pharmacy

Volumn 62, Issue SUPPL. 2, 2005, Pages

  Devlin, John W ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Costs; Critical illness; Decision making; Dosage forms; Drug administration; Drug administration routes; Economics; Formularies; Gastrointestinal drugs; Gastrointestinal hemorrhage; Hospitals; Pharmacodynamics; Pharmacokinetics; Protocols; Stability; Storage

Indexed keywords

ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PREVACID SOLUTAB; PROTON PUMP INHIBITOR;

BIOEQUIVALENCE; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CRITICAL ILLNESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG FORMULATION; DRUG SAFETY; HUMAN; INTENSIVE CARE UNIT; NOSE FEEDING; PALATABILITY; PEPTIC ULCER BLEEDING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; TREATMENT OUTCOME;

EID: 18644378880     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/62.10_supplement_2.s24     Document Type: Conference Paper

References (48)

1. Merli GJ, Vanscoy GJ, Rihn TL et al. Applying scientific criteria to therapeutic interchange: a balanced analysis of low-molecular-weight heparins. J Thromb Thrombolysis. 2001; 11:247-59.
2. Draft ASHP Guidelines for Medication Use Policy Development. http://www.ashp.org/bestpractices/ draft_guidance/Guidelines_on_Med-Use_Policy. pdf. Accessed 18 Dec 2004.
3. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash). 2000; 40:52-62.
4. Protonix i.v. package insert. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; December 2004.
5. Prevacid i.v. package insert. Lake Forest, IL: TAP Pharmaceuticals Inc.; May 2004.
6. Kovacs TO, Lee CQ, Chiu YL et al. Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis. Aliment Pharmacol Ther. 2004; 20:883-9.
7. Metz DC, Pratha V, Martin P et al. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2000; 95:626-33.
8. Lew EA, Pisegna JR, Starr JA et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology. 2000; 118:696-704.
9. Brunner G, Luna P, Hartmann M et al. Optimizing the intragastric pH as a supportive therapy in upper GI bleeding. Yale J Biol Med. 1996; 69:225-31.
10. Vorder Bruegge WF, Peura DA. Stress-related mucosal damage: review of drug therapy. J Clin Gastroenterol. 1990; 12(suppl 2):S35-40.
11. Labenz J, Peitz U, Leusing C et al. Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study. Gut. 1997; 40:36-41.
12. Kiilerich S, Rannem T, Elsborg L. Effect of intravenous infusion of omeprazole and ranitidine on twenty-four-hour intragastric pH in patients with a history of duodenal ulcer. Digestion. 1995; 56:25-30.
13. Gisbert JP, Gonzalez L, Calvet X et al. Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther. 2001; 15:917-26.
14. Barkun A, Racz I, van Rensburg C et al. Prevention of peptic ulcer rebleeding using continuous infusion of pantoprazole vs. ranitidine: a multicenter, multinational, randomized, double-blind, parallel-group comparison. Gastroenterology. 2004; 126:A78. Abstract.
15. Somberg L, Karlstadt R, Blatcher D et al. Intermittent intravenous pantoprazole (P) maintains control of gastric pH in intensive care unit patients. Am J Gastroenterol. 2002; 97:S47. Abstract.
16. Leontiadis GI, McIntyre L, Sharma VK et al. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2004; (3):CD002094.
17. Baldi F, Malfertheiner P. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. Digestion. 2003; 67:1-5.
18. Freston JW, Chiu YL, Mulford DJ et al. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment Pharmacol Ther. 2003; 17:361-7.
19. Taneja R, Shaffer DI, Scarim JA. Feasibility of dosing lansoprazole orally disintegrating tablets (Prevacid* SoluTab™) via nasogastric tube: an in vitro study. Pharmacotherapy. 2003; 23:1338-9. Abstract 73.
20. Gremse DA, Donnelly JR, Kukulka MJ et al. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe. Aliment Pharmacol Ther. 2004; 19:1211-5.
21. Sostek MB, Chen Y, Skammer W et al. Esomeprazole administered through a nasogastric tube provides bioavailability similar to oral dosing. Aliment Pharmacol Ther. 2003; 18:581-6.
22. Spencer CM, Faulds D. Esomeprazole. Drugs. 2000; 60:321-9.
23. Doan TT, Wang Q, Griffin JS et al. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. Am J Health-Syst Pharm. 2001; 58:1512-9.
24. Sharma VK, Peyton B, Spears T et al. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. Aliment Pharmacol Ther. 2000; 14:887-92.
25. Song JC, Quercia RA, Fan C et al. Pharmacokinetic comparison of omeprazole capsules and a simplified omeprazole suspension. Am J Health-Syst Pharm. 2001; 58:689-94.
26. Paul J, Ferron GM, Ku S et al. Pantoprazole bicarbonate suspension (PBS) provides oral bioavailability comparable to tablet. Crit Care Med. 2000; 28:A184. Abstract.
27. Kale-Pradhan PB, Landry HK, Sypula WT. Esomeprazole for acid peptic disorders. Ann Pharmacother. 2002; 36:655-63.
28. Dunn A, White CM, Reddy P et al. Delivery of omeprazole and lansoprazole granules through a nasogastric tube in vitro. Am J Health-Syst Pharm. 1999; 56:2327-30.
29. White CM, Kalus JS, Quercia R et al. Delivery of esomeprazole magnesium enteric-coated pellets through small caliber and standard nasogastric tubes and gastrostomy tubes in vitro. Am J Health-Syst Pharm. 2002; 59:2085-8.
30. Ferron GM, Ku S, Abell M et al. Oral bioavailability of pantoprazole suspended in sodium bicarbonate solution. Am J Health-Syst Pharm. 2003; 60:1324-9.
31. Levy MJ, Seelig CB, Robinson NJ et al. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci. 1997; 42:1255-9.
32. Lasky MR, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma. 1998; 44:527-33.
33. Khuroo MS, Yattoo GN, Javid G et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med. 1997; 336:1054-8.
34. Javid G, Masoodi I, Zargar SA et al. Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer. Am J Med. 2001; 111:280-4.
35. Laine L, Margolis V, Bagin RG et al. Double-blind trial of omeprazole immediate-release oral suspension (OME-IR SUSP) vs. intravenous cimetidine (I CIM) for prevention of upper gastrointestinal (GI) bleeding in critically ill patients. Gastroenterology. 2004; 126:A-77-8. Abstract 608.
36. Erstad BL, Camamo JM, Miller MJ et al. Impacting cost and appropriateness of stress ulcer prophylaxis at a university medical center. Crit Care Med. 1997; 25:1678-84.
37. Fu A, Martin JE, Gregor JC. Proton pump inhibitor infusion as an adjunct to endoscopic therapy for bleeding peptic ulcer disease: a cost-benefit analysis. Am J Gastroenterol. 2001; 96:5266. Abstract 849.
38. Barkun AN, Herba K, Adam V et al. The cost-effectiveness of high-dose oral proton pump inhibition after endoscopy in the acute treatment of peptic ulcer bleeding. Aliment Pharmacol Ther. 2004; 20:195-202.
39. Gagnon YM, Levy AR, Eloubeidi MA et al. Cost implications of administering intravenous proton pump inhibitors to all patients presenting to the emergency department with peptic ulcer bleeding. Value Health. 2003; 6:457-65.
40. Enns RA, Gagnon YM, Rioux KP et al. Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding. Aliment Pharmacol Ther. 2003; 17:225-33.
41. Spiegel BM, Ofman JJ, Woods K et al. Minimizing recurrent peptic ulcer hemorrhage after endoscopic hemostasis: the cost-effectiveness of competing strategies. Am J Gastroenterol. 2003; 98:86-97.
42. Lee KK, You JH, Wong IC et al. Cost-effectiveness analysis of high-dose omeprazole infusion as adjuvant therapy to endoscopic treatment of bleeding peptic ulcer. Gastrointest Endosc. 2003; 57:160-4.
43. Devlin JW, Welage LS. The cost-effectiveness of proton pump inhibitors for bleeding peptic ulcers: The unanswered questions. Crit Care Med. 2004; 32:1415-6.
44. Roberts KA. Best practices in the development of clinical practice guidelines. J Healthc Qual. 1998; 20:16-20, 32.
45. Devlin JW, Claire KS, Dulchavsky SA et al. Impact of trauma stress ulcer prophylaxis guidelines on drug cost and frequency of major gastrointestinal bleeding. Pharmacotherapy. 1999; 19:452-60.
46. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. Am J Health-Syst Pharm. 1999; 56:347-79. http://www.ashp.org/bestpractices/tg/TG_StressUlcer. pdf. Accessed 1 Apr 2005.
47. Barkun A, Bardou M, Marshall JK; Non-variceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2003; 139:843-57.
48. Jensen DM. Spots and clots - leave them or treat them? Why and how to treat. Can J Gastroenterol. 1999; 13:413-5.